B-ALL with recurrent genetic abnormalities

Siti Zaleha s.Abdullah; Tin Tin Thein; Aye Aye Wynn; Lia Natasha Amit

dc.contributor.author	Siti Zaleha s.Abdullah
dc.contributor.author	Tin Tin Thein
dc.contributor.author	Aye Aye Wynn
dc.contributor.author	Lia Natasha Amit
dc.date.accessioned	2024-10-22T01:39:29Z
dc.date.available	2024-10-22T01:39:29Z
dc.date.issued	2024-10-14
dc.identifier.uri	http://oer.ums.edu.my/handle/oer_source_files/2834
dc.description.abstract	B-lymphoblastic leukemia/lymphoma (B-ALL) is common in children with 75% of cases occurring in children aged less than 6 years. It is a group of diseases characterized by recurrent genetic abnormalities, including balanced translocations and chromosome number abnormalities. New genetic anomalies that define novel B-ALL subtypes have been reported recently. Those included have been chosen because they are associated with distinctive clinical or phenotypic properties with important prognostic implications. The treatment of B-ALL is rapidly evolving due to an increased understanding of the genetic heterogeneity of B-ALL, which has contributed to the development of numerous novel therapies. Key words: B-ALL, B-lymphoblastic leukaemia/lymphoma, recurrent genetic abnormalities	en_US
dc.language.iso	en	en_US
dc.subject	B-ALL, Leukaemia, recurrent genetic abnormalities	en_US
dc.title	B-ALL with recurrent genetic abnormalities	en_US
dc.type	Presentation	en_US